IAS Gyan

Daily News Analysis


18th December, 2021 Science and Technology

Disclaimer: Copyright infringement not intended.


  • The World Health Organization issued an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus.



  • Covovax is the Indian version of a Covid-19 vaccine developed by Novavax Inc and manufactured under licence by the Serum Institute of India (SII).
  • It is a recombinant protein vaccine that uses spike proteins to teach the body how to develop immunity against the novel coronavirus.
  • Covovax has greater efficacy as a booster dose than Covishield.
  • Covovax requires two doses and is stable at 2 to 8 degrees Celsius refrigerated temperatures.


Final word

  • This listing aims to increase access, particularly in lower income countries, 41 of which have still not been able to vaccinate 10% of their populations, while 98 countries have not reached 40%.
  • WHO approval is a good news for India, and that the government shouldn’t waste much time in rolling out Covovax as a booster dose.



Read: https://www.iasgyan.in/blogs/types-of-vaccines